{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-100771","form_type":"8-K","ticker":"TEVA","cik":"0000818686","company_name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","filed_at":"2024-04-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:22.068821+00:00","generated_at":"2026-06-03T21:19:03.369814+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Teva realigns reporting segments; Canada moved to International Markets from North America","bullets":["Canada will be reported as part of International Markets segment, not North America, effective Q1 2024.","Recast 2023 and 2022 segment data shows US segment revenue $7,731M (2023) and segment profit $2,394M.","Canada 2023 revenue $393M, down 12.5% from $449M in 2022, included in International Markets.","No impact on previously reported consolidated financial statements; prior periods restated for comparability."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-100771","json":"https://secwatch.observer/filing/0001193125-24-100771.json","markdown":"https://secwatch.observer/filing/0001193125-24-100771.md","text":"https://secwatch.observer/filing/0001193125-24-100771.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/818686/000119312524100771/0001193125-24-100771-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/818686/000119312524100771/d800395d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T21:19:03.369814+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}